Related Experiment Video
Updated: Jul 19, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Deciphering leukemic B-cell chronic lymphoproliferative disorders
Valérie Ugo1, Nathalie Leporrier, Véronique Salaun
1Laboratoire d'Hématologie, CHU Brest, France.
Insights
Diagnosing leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) is challenging. This study identified distinct subgroups within atypical B-CLPD, aiding in better classification and treatment strategies for these hematologic malignancies.
Area of Science:
- Hematology
- Oncology
- Immunophenotyping
Background:
- Leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) present diagnostic challenges.
- Atypical cases require further subclassification for accurate prognosis and treatment.
Purpose of the Study:
- To investigate atypical B-CLPD cases using a multicentric approach.
- To identify homogeneous subgroups within B-CLPD for improved diagnostic and therapeutic strategies.
Main Methods:
- Prospective study of 165 new consecutive leukemic B-CLPD patients with a Royal Marsden Hospital score ≤3.
- Morphological examination, CD5, cyclin D1, CD20, and p27 expression analysis.
Main Results:
- Morphology was diagnostic in only 20% of cases (all CD5 negative).
- Cyclin D1 positivity (26 cases) indicated poorer survival, warranting systematic testing.
- CD20 expression delineated two subgroups among CD5 positive, cyclin D1 negative B-CLPD: CD20 dim (17 patients) resembling B-cell chronic lymphocytic leukemia (B-CLL), and CD20 bright (51 patients) showing heterogeneity and lower p27, suggesting a proliferative component.
Conclusions:
- Systematic cyclin D1 determination is recommended for atypical B-CLPD.
- CD20 expression helps distinguish a homogeneous subgroup similar to B-CLL (CD20 dim).
- The heterogeneous CD20 bright subgroup requires further genomic investigation due to potential proliferative and aggressive disease characteristics, suggesting exclusion from B-CLL therapeutic trials.
Abstract:
Diagnosis of leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) is a frequent challenge in hematology. In this multicentric study, we prospectively studied 165 new consecutive leukemic patients with B-CLPD selected on the basis of Royal Marsden Hospital scoring system < or =3. The primary aim of the study was to try to decipher the atypical cases and identify homogenous subgroups. Overall, morphological examination contributed to diagnosis in only 20% cases, all of them CD5 negative. Thirty additional cases were CD5 negative suggestive of leukemic marginal zone lymphoma in most cases. The significantly poorer survival of the 26 cyclin D1 positive cases justifies recommending its systematic determination among atypical B-CLPD. CD20 expression segregated clearly two subgroups among CD5 positive cyclin D1 negative B-CLPD. The 17 patients with the CD20 dim profile represent a homogeneous subgroup very close to typical B-cell chronic lymphocytic leukemia (B-CLL) on morphological, phenotypical and cytogenetical criteria. In contrast, the subgroup of 51 patients with a CD20 bright profile is heterogeneous. Their significantly lower p27 expression level suggest the presence of a proliferative component, underlying a more aggressive disease. Further genomic studies are warranted to establish their precise nature. These cases should not be included in the same therapeutic trials as B-CLL.
More Related Videos
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
